EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics announces that a common LAM-002 mechanism in cancer and neurodegenerative diseases shows antitumor activity in the clinic and hope for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Start of Phase II Trial of LAM-002A (apilimod dimesylate) for Treatment of COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"OrphAI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphAI Therapeutics Receives Orphan Drug Designation for AIT-101 as a Treatment for Amyotrophic Lateral Sclerosis in the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Apilimod mesylate

    Menu

    Apilimod mesylate

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              OrphAI Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrphAI Therapeutics Receives Orphan Drug Designation for AIT-101 as a Treatment for Amyotrophic Lateral Sclerosis in the European Union

              Details:

              AIT-101 (apilimod dimesylate) is a first-in-class, potent and highly selective inhibitor of the lipid kinase PIKfyve. It is being developed for the treatment of amyotrophic lateral sclerosis.

              Lead Product(s): Apilimod mesylate

              Therapeutic Area: Neurology Product Name: AIT-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 15, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AI Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)

              Details:

              AIT-101 (apilimod dimesylate) is a potent and highly selective inhibitor of the lipid kinase PIKfyve, which activates the transcription factor TFEB which drives the increased clearance of toxic protein aggregates. It is being investegated for treating C9ORF72 ALS.

              Lead Product(s): Apilimod mesylate

              Therapeutic Area: Neurology Product Name: AIT-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AI Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AI Therapeutics Announces Start of Phase II Trial of LAM-002A (apilimod dimesylate) for Treatment of COVID-19 Patients

              Details:

              The randomized, double-blind, placebo-controlled study will enroll up to 142 outpatients to evaluate the safety, tolerability, and efficacy of LAM-002A in reducing viral load in subjects with a confirmed COVID-19.

              Lead Product(s): Apilimod mesylate

              Therapeutic Area: Infections and Infectious Diseases Product Name: LAM-002

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kintai Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AI Therapeutics announces that a common LAM-002 mechanism in cancer and neurodegenerative diseases shows antitumor activity in the clinic and hope for ALS

              Details:

              Company receives FDA guidance for pivotal trial design in follicular lymphoma to support accelerated and full approval.

              Lead Product(s): Apilimod mesylate,Rituximab,Atezolizumab

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 16, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY